Adjuvant immunotherapy with nonviablemycobacterium smegmatis in resected primary lung carcinoma a randomized clinical trial of 219 patients
Open Access
- 15 February 1984
- Vol. 53 (4) , 906-912
- https://doi.org/10.1002/1097-0142(19840215)53:4<906::aid-cncr2820530415>3.0.co;2-h
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Systemic complications of mer immunotherapy of cancer.Pulmonary granulomatosis and rashCancer, 1979
- BCG as Adjuvant Immunotherapy for NeoplasiaAnnual Review of Medicine, 1977
- Immunology of bronchial carcinoma.Thorax, 1976
- IMMUNOTHERAPY WITH NONVIABLE MICROBIAL COMPONENTSAnnals of the New York Academy of Sciences, 1976
- Granuloma formation in patients receiving BCG immunotherapy.Journal of Clinical Pathology, 1976
- Hazards and Complications of BCG ImmunotherapyMedical Clinics of North America, 1976
- Nonspecific Resistance to Infection Induced in Mice by a Water-Soluble Adjuvant Derived from Mycobacterium smegmatisThe Journal of Infectious Diseases, 1976
- Nonspecific Macrophage Activation by Systemic AdjuvantsInternational Archives of Allergy and Immunology, 1976
- Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants.Proceedings of the National Academy of Sciences, 1975
- Eighty years of immunotherapy: a review of immunological methods used for the treatment of human cancerBritish Journal of Cancer, 1972